Search Result

Results for "

thrombus

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Apoptosis (2) Bacterial (1) Calcium Channel (2) Carboxypeptidase (1) Endogenous Metabolite (1) Factor Xa (3) Factor XI (1) Integrin (5) NADPH Oxidase (1) P2Y Receptor (1) PDI (2) Phospholipase (1) Platelet-activating Factor Receptor (PAFR) (1) Prostaglandin Receptor (3) Protease Activated Receptor (PAR) (2) Thrombin (1)
By Research Areas:	Cancer (3) Cardiovascular Disease (23) Inflammation/Immunology (2)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-114086

ML359	PDI	Cardiovascular Disease
ML359 is a potent, selctive and reversible inhibitor of protein disulfide isomerase (PDI), with an IC₅₀ of 250 nM. ML359 can prevent thrombus formation in vivo .

HY-10267

Eribaxaban PD-0348292	Factor Xa	Cardiovascular Disease
Eribaxaban (PD-0348292) is an orally active and selective FXa inhibitor with a K_i value of 0.32 nM. Eribaxaban reduces thrombus formation .

HY-W654264

2-Methylbutyrylcarnitine chloride	Endogenous Metabolite Integrin	Cardiovascular Disease
2-Methylbutyrylcarnitine (chloride) is a gut microbial metabolite which binds to integrin α2β1 in platelets, potentiating cytosolic phospholipase A2 (cPLA2) activation and platelet hyperresponsiveness. 2-Methylbutyrylcarnitine (chloride) enhances platelet hyperreactivity and thrombus formation in mice. 2-Methylbutyrylcarnitine (chloride) is a branched-chain acylcarnitine .

HY-13965

Parmodulin 2 2 Publications Verification ML161	Protease Activated Receptor (PAR)	Cardiovascular Disease
Parmodulin 2 (ML161) is an allosteric inhibitor of protease-activated receptor 1 (PAR1) with an IC₅₀ of 0.26 μM . Parmodulin 2 is a potent and non-competitive inhibitor of SFLLRN-induced P-selectin expression leading to inhibition of platelet aggregation in vitro and platelet thrombus formation in vivo .

HY-107588

TC-I 15 1 Publications Verification	Integrin	Cardiovascular Disease
TC-I 15 (TC-I-15) is a type of allosteric collagen-binding integrin α2β1 inhibitor, and it also inhibits α1β1 and α11β1. TC-I 15 inhibits platelet adhesion to collagen and thrombus deposition. TC-I 15 prevents the formation of a pre-metastatic microenvironment by inhibiting the uptake of cancer-associated fibroblast (CAF) extracellular vesicles (EVs) by lung fibroblasts, which reduces the metastasis of salivary gland adenocystic carcinoma (SACC) to the lungs in mouse models, .

HY-105392

LB30057 CI-1028; PD 172524	Thrombin	Cardiovascular Disease
LB30057 (CI-1028) is an orally active selective thrombin inhibitor with an IC₅₀ value of 0.38 nM for human thrombin. LB30057 can be used in the study of the thrombus model .

HY-116400

BN 50341	Calcium Channel Platelet-activating Factor Receptor (PAFR)	Cardiovascular Disease
BN 50341 is an orally active anticalcic agent and a benzazepine derivative. BN 50341 decreases the in vivo electrically induced thrombus formation in rat or guinea-pig artery and can be utilized in cardiovascular research .

HY-118410

L-738167	Integrin	Cardiovascular Disease
L-738167 is an orally active fibrogen receptor antagonist that prevents the binding of fibrinogen to GP IIb/IIIa. L-738167 can be utilized in thrombus research .

HY-116281

ICI D1542	Prostaglandin Receptor	Cardiovascular Disease
ICI D1542 is a selective and potent inhibitor of thromboxane A2 (TXA2) synthase and the thromboxane A2 receptor (TP-receptor). ICI D1542 is effective at preventing thrombus formation by redirection of arachidonic acid metabolism .

HY-172905

BCX-3607	Others	Cardiovascular Disease
BCX-3607 is an orally active tissue factor/factor VIIa (TF-FVIIa) inhibitor (IC₅₀: 4 nM). BCX-3607 blocks the extrinsic coagulation pathway by inhibiting the TF-FVIIa complex and significantly prolongs the prothrombin time (PT). BCX-3607 has a higher selectivity for TF-FVIIa than other serine proteases (such as thrombin, FXa, etc.). BCX-3607 can reduce thrombus weight and inflammatory response, and has both anti-thrombotic and anti-inflammatory effects. BCX-3607 can be used in the study of thrombosis-related diseases .

HY-107023

AZD 9684	Carboxypeptidase	Cardiovascular Disease
AZD 9684 is a carboxypeptidase U inhibitor,and can be used for study of thrombus .

HY-101727

Nexopamil racemate	Calcium Channel 5-HT Receptor	Cardiovascular Disease
Nexopamil racemate is the racemate of Nexopamil. Nexopamil is a combined Ca ²⁺/5-HT₂ antagonist on thrombus formation in vivo and on platelet aggregation in vitro.

HY-110043

(±)-Clopidogrel hydrochloride	P2Y Receptor	Cardiovascular Disease
(±)-Clopidogrel hydrochloride is an antithrombotic agent that is ADP-selective and orally available. (±)-Clopidogrel hydrochloride inhibits platelet aggregation by inhibiting the binding of ADP to its platelet receptors .

HY-W612338

9-Oxononanoic acid 9-ONA	Phospholipase Prostaglandin Receptor	Cardiovascular Disease
9-Oxononanoic acid (9-ONA) is secondary reaction product of lipid peroxidation. 9-Oxononanoic acid induces phospholipase A2 (PLA2) activity and thromboxane A2 (HY-113350) production (TXA2). 9-Oxononanoic acid induces the platelet aggregation in human blood. 9-Oxononanoic acid is orally active .

HY-159896

PAR4 antagonist 8	Protease Activated Receptor (PAR)	Cardiovascular Disease
PAR4 antagonist 8 (Compound 20f) is an effective, orally active, and selective PAR4 antagonist with an IC₅₀ value of 15.32 nM. PAR4 antagonist 8 exhibits favorable pharmacokinetic properties. PAR4 antagonist 8 not only effectively inhibits human platelet aggregation induced by PAR4 agonists (IC₅₀ = 6.39 nM) but also inhibits mouse platelet aggregation. PAR4 antagonist 8 can be used in antithrombotic research .

HY-P991124

Cenvacibart	Factor XI	Cardiovascular Disease
Cenvacibart is a monoclonal antibody with anticoagulant activity, targeting human coagulation factor XI (F11). Cenvacibart blocks the role of coagulation factor XI in the coagulation cascade, reducing thrombus formation. Cenvacibart is promising for research of thrombotic diseases .

HY-167736

(2R)-Naroparcil	Others	Others
(2R)-Naroparcil is an isomer of Naroparcil, a 4-methylumbelliferyl beta-D-xyloside analog that plays a role in promoting vascular smooth muscle cell proliferation and has been shown to inhibit thrombus formation in the Wessler slough model.

HY-125856

Milvexian 1 Publications Verification BMS-986177; JNJ-70033093	Factor Xa	Cardiovascular Disease
Milvexian is an orally bioavailable, small-molecule, reversible, direct antagonists of factor Xia, with the K_i of 0.11, 0.38, 0.64, 490, 350 nM for human, rabbit, dog, rat, mouse, respectively. Milvexian shows anti-thrombosis activity in vitro and in vivo, and can be used for thrombus study .

HY-170655

PDI-IN-4	PDI Integrin	Cardiovascular Disease
PDI-IN-4 (Compound 14d) is an inhibitor of protein disulfide isomerase, with an IC₅₀ value of 0.48 μM. PDI-IN-4 suppresses platelet aggregation and thrombus formation by attenuating GPIIb/IIIa activation without significantly causing cytotoxicity. PDI-IN-4 can be used in research on thrombosis .

HY-123400A

iso-Samixogrel iso-DTTX30; iso-DT-TX 30 SE	Prostaglandin Receptor	Cardiovascular Disease
Iso-Samixogrel (iso-DTTX30) is a combined thromboxane A2 receptor blocker and thromboxane synthetase inhibitor that exhibits potent antithrombotic activity. Iso-Samixogrel effectively eliminates recurrent arterial thrombus formation and inhibits collagen-induced platelet aggregation ex vivo. Iso-Samixogrel also prolongs sublingual bleeding time, demonstrating its biological efficacy in managing thrombosis.

HY-113533

Resolvin D4 RvD4	Bacterial	Inflammation/Immunology
Resolvin D4 (RvD4), a specialized proresolving mediator, can be produced in bioactive levels during S. aureus infection .

HY-111447

VAS 3947	NADPH Oxidase Apoptosis	Cardiovascular Disease Cancer
VAS 3947, a specific NADPH oxidase (NOX) inhibitor, exerts a potent antiplatelet effect. VAS3947 induces apoptosis independently of anti-NOX activity, via UPR activation, mainly due to aggregation and misfolding of proteins .

HY-144658

FXIa-IN-8	Factor Xa	Cardiovascular Disease
FXIa-IN-8 is a potent and selective FXIa inhibitor with an IC₅₀ of 14.2 nM. FXIa-IN-8 shows antithrombotic activity without increasing the bleeding risk and obvious toxicitysup>[1].

HY-110112

BTT-3033	Integrin Apoptosis	Cardiovascular Disease Inflammation/Immunology Cancer
BTT-3033 is an orally active conformation-selective inhibitor of α2β1 (EC50: 130 nM) by binding to the α2I domain. BTT-3033 inhibits platelet binding to collagen Ⅰ and cell proliferation, and induces cell apoptosis. BTT-3033 can be used in the research of prostate cancer, inflammation and cardiovascular disease .

Cat. No.	Product Name

HY-L136

Coagulation and Anti-coagulation Compound Library	1,184 compounds
Coagulation, also known as clotting, is the process in which blood changes from a liquid to a solid gel to form a blood clot. Thrombin, which is accurately and evenly generated in the injured part of blood vessels, is a key effector enzyme of the blood coagulation system and participates in many important biological processes, such as platelet activation, fibrinogen conversion to fibrin network, coagulation feedback amplification, etc. At the same time, to avoid the accidental formation of thrombus in the body, there is also an anticoagulant mechanism that inhibits blood coagulation. Normal coagulation mechanism represents a balance between the pro-coagulant pathway in the injured site and anti-coagulant pathway beyond it. The blood coagulation system may be out of balance during the perioperative period or critical illness, which may lead to thrombosis or excessive bleeding. Therefore, the physiological study of coagulation balance is an important basis for clinical diagnosis and treatment of the abnormal coagulation process. MCE supplies a unique collection of 1,184 compounds targeting key proteins in coagulation and anti-coagulation system. MCE Coagulation and Anti-coagulation Compound Library is a useful tool for study the mechanism of coagulation and anticoagulation.

Coagulation and Anti-coagulation Compound Library

1,184 compounds

Coagulation, also known as clotting, is the process in which blood changes from a liquid to a solid gel to form a blood clot. Thrombin, which is accurately and evenly generated in the injured part of blood vessels, is a key effector enzyme of the blood coagulation system and participates in many important biological processes, such as platelet activation, fibrinogen conversion to fibrin network, coagulation feedback amplification, etc. At the same time, to avoid the accidental formation of thrombus in the body, there is also an anticoagulant mechanism that inhibits blood coagulation.

Normal coagulation mechanism represents a balance between the pro-coagulant pathway in the injured site and anti-coagulant pathway beyond it. The blood coagulation system may be out of balance during the perioperative period or critical illness, which may lead to thrombosis or excessive bleeding. Therefore, the physiological study of coagulation balance is an important basis for clinical diagnosis and treatment of the abnormal coagulation process.

MCE supplies a unique collection of 1,184 compounds targeting key proteins in coagulation and anti-coagulation system. MCE Coagulation and Anti-coagulation Compound Library is a useful tool for study the mechanism of coagulation and anticoagulation.

Cat. No.	Product Name	Target	Research Area

HY-P3052

RGDV	Peptides	Cancer
RGDV is a platelet aggregation inhibitor. RGDV inhibits platelet-dependent thrombus formation. RGDV is used for tumor recognition via the targeting effect .

HY-P3082

SKF 106760	Peptides	Cardiovascular Disease
SKF 106760 is a potent platelet fibrin receptor (glycoprotein IIb/IIIa) antagonist with significant antiplatelet and antithrombotic activities. SKF 106760 inhibits platelet aggregation in dogs in vitro and prevents thrombus formation in stenotic carotid arteries. SKF 106760 has also shown elimination effects against aspirin-resistant thrombi that develop in the setting of high-grade stenosis .

Cat. No.	Product Name	Target	Research Area

HY-P991124

Cenvacibart	Factor XI	Cardiovascular Disease
Cenvacibart is a monoclonal antibody with anticoagulant activity, targeting human coagulation factor XI (F11). Cenvacibart blocks the role of coagulation factor XI in the coagulation cascade, reducing thrombus formation. Cenvacibart is promising for research of thrombotic diseases .

2-Methylbutyrylcarnitine chloride	Cardiovascular Disease Structural Classification Natural Products Classification of Application Fields Source classification Endogenous metabolite Disease Research Fields	Endogenous Metabolite Integrin
2-Methylbutyrylcarnitine (chloride) is a gut microbial metabolite which binds to integrin α2β1 in platelets, potentiating cytosolic phospholipase A2 (cPLA2) activation and platelet hyperresponsiveness. 2-Methylbutyrylcarnitine (chloride) enhances platelet hyperreactivity and thrombus formation in mice. 2-Methylbutyrylcarnitine (chloride) is a branched-chain acylcarnitine .

9-Oxononanoic acid 9-ONA	Structural Classification Arachis hypogaea L. Leguminosae Ketones, Aldehydes, Acids Source classification Plants	Phospholipase Prostaglandin Receptor
9-Oxononanoic acid (9-ONA) is secondary reaction product of lipid peroxidation. 9-Oxononanoic acid induces phospholipase A2 (PLA2) activity and thromboxane A2 (HY-113350) production (TXA2). 9-Oxononanoic acid induces the platelet aggregation in human blood. 9-Oxononanoic acid is orally active .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks